<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808418</url>
  </required_header>
  <id_info>
    <org_study_id>4783-12</org_study_id>
    <nct_id>NCT00808418</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>A Phase 1 Study of Weekly Elesclomol Sodium Plus Docetaxel and Concomitant Prednisone in Subjects With Metastatic Castration Refractory Prostate Cancer (m-CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This aim of this study is to determine the safety and tolerability of elesclomol sodium at
      escalating doses (ultimately identifying the maximum tolerated dose) when combined with a
      fixed dose of docetaxel and concomitant prednisone. This study will also characterize the
      pharmacokinetics of elesclomol and docetaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This aim of this study is to determine the safety and tolerability of elesclomol sodium at
      escalating doses (ultimately identifying the maximum tolerated dose) when combined with a
      fixed dose of docetaxel and concomitant prednisone. This study will also characterize the
      pharmacokinetics of elesclomol and docetaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the safety and tolerability of escalating doses of elesclomol sodium in combination with a fixed dose of docetaxel and concomitant prednisone administered weekly to m-CRPC subjects</measure>
    <time_frame>Jan 2011</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the MTD of elesclomol sodium when administered with 30 mg/m2 weekly docetaxel</measure>
    <time_frame>Jan 2011</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the pharmacokinetics of elesclomol sodium and docetaxel in this population</measure>
    <time_frame>Jan 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate anti-tumor activity at the MTD in castration refractory prostate cancer</measure>
    <time_frame>Jan 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate OS</measure>
    <time_frame>Jan 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of elesclomol metabolites</measure>
    <time_frame>Jan 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elesclomol Sodium</intervention_name>
    <description>Chemotherapy agent</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Chemotherapy agent</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Confirmed metastatic prostate cancer

          -  No more than one prior chemotherapy on which the disease progressed

          -  ECOG performance status of less than or equal to 2

          -  Adequate bone marrow, renal and hepatic functions as defined in the protocol

          -  Neuropathy less than or equal to 2

          -  Reliable venous access for frequent study drug infusions

        Exclusion Criteria

          -  Significant cardiovascular disease

          -  Known active brain metastases

          -  Subjects that have received treatment for other malignancies with in the past 5 years

          -  Other clinically significant uncontrolled conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pacific Coast Hematology/Oncology Medical Group</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Maryland</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Dakota Clinic</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center, Cancer Therapy &amp; Research Center, Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>January 31, 2014</last_update_submitted>
  <last_update_submitted_qc>January 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>castration</keyword>
  <keyword>refractory</keyword>
  <keyword>elesclomol</keyword>
  <keyword>sodium</keyword>
  <keyword>docetaxel</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

